SMYD3 and hepatocellular carcinoma: Particularly in HBV-induced HCC, SMYD3 may directly interact with HBX to activate oncogenic pathways, such as the AKT-, ERK-, and AP-1 signaling, promoting the development of HCC in HBV-infected liver cells.